Scientific Resources
KT-253, a highly potent and selective heterobifunctional MDM2 degrader for the treatment of wildtype p53 tumors with superior potency and differentiated biological activity compared to small molecule inhibitors (SMI)
American Association for Cancer Research Annual Meeting, April 8-13, 2022